743 related articles for article (PubMed ID: 28351398)
21. CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies.
Ogino S; Cantor M; Kawasaki T; Brahmandam M; Kirkner GJ; Weisenberger DJ; Campan M; Laird PW; Loda M; Fuchs CS
Gut; 2006 Jul; 55(7):1000-6. PubMed ID: 16407376
[TBL] [Abstract][Full Text] [Related]
22. Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer.
Han SW; Lee HJ; Bae JM; Cho NY; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Park JG; Kang GH; Kim TY
Int J Cancer; 2013 May; 132(9):2209-16. PubMed ID: 23034738
[TBL] [Abstract][Full Text] [Related]
23. Identifying CpG sites with different differential methylation frequencies in colorectal cancer tissues based on individualized differential methylation analysis.
Yan H; He J; Guan Q; Cai H; Zhang L; Zheng W; Qi L; Zhang S; Liu H; Li H; Zhao W; Yang S; Guo Z
Oncotarget; 2017 Jul; 8(29):47356-47364. PubMed ID: 28537885
[TBL] [Abstract][Full Text] [Related]
24. Nuclear maspin expression correlates with the CpG island methylator phenotype and tumor aggressiveness in colorectal cancer.
Kim JH; Cho NY; Bae JM; Kim KJ; Rhee YY; Lee HS; Kang GH
Int J Clin Exp Pathol; 2015; 8(2):1920-8. PubMed ID: 25973084
[TBL] [Abstract][Full Text] [Related]
25. Comprehensive analysis of CpG island methylator phenotype (CIMP)-high, -low, and -negative colorectal cancers based on protein marker expression and molecular features.
Zlobec I; Bihl M; Foerster A; Rufle A; Lugli A
J Pathol; 2011 Nov; 225(3):336-43. PubMed ID: 21660972
[TBL] [Abstract][Full Text] [Related]
26. CpG island methylator phenotype is an independent predictor of survival after curative resection for colorectal cancer: A prospective cohort study.
Kim CH; Huh JW; Kim HR; Kim YJ
J Gastroenterol Hepatol; 2017 Aug; 32(8):1469-1474. PubMed ID: 28087988
[TBL] [Abstract][Full Text] [Related]
27. CpG island methylator phenotype-low (CIMP-low) colorectal cancer shows not only few methylated CIMP-high-specific CpG islands, but also low-level methylation at individual loci.
Kawasaki T; Ohnishi M; Nosho K; Suemoto Y; Kirkner GJ; Meyerhardt JA; Fuchs CS; Ogino S
Mod Pathol; 2008 Mar; 21(3):245-55. PubMed ID: 18204436
[TBL] [Abstract][Full Text] [Related]
28. DNA methylation subgroups and the CpG island methylator phenotype in gastric cancer: a comprehensive profiling approach.
Loh M; Liem N; Vaithilingam A; Lim PL; Sapari NS; Elahi E; Mok ZY; Cheng CL; Yan B; Pang B; Salto-Tellez M; Yong WP; Iacopetta B; Soong R
BMC Gastroenterol; 2014 Mar; 14():55. PubMed ID: 24674026
[TBL] [Abstract][Full Text] [Related]
29. Unique patterns of CpG island methylation in inflammatory bowel disease-associated colorectal cancers.
Olaru AV; Cheng Y; Agarwal R; Yang J; David S; Abraham JM; Yu W; Kwon JH; Lazarev M; Brant SR; Marohn MR; Hutcheon DF; Harpaz N; Meltzer SJ; Mori Y
Inflamm Bowel Dis; 2012 Apr; 18(4):641-8. PubMed ID: 21830278
[TBL] [Abstract][Full Text] [Related]
30. Clinicopathologic Risk Factor Distributions for MLH1 Promoter Region Methylation in CIMP-Positive Tumors.
Levine AJ; Phipps AI; Baron JA; Buchanan DD; Ahnen DJ; Cohen SA; Lindor NM; Newcomb PA; Rosty C; Haile RW; Laird PW; Weisenberger DJ
Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):68-75. PubMed ID: 26512054
[TBL] [Abstract][Full Text] [Related]
31. Multiple sporadic colorectal cancers display a unique methylation phenotype.
Gonzalo V; Lozano JJ; Alonso-Espinaco V; Moreira L; Muñoz J; Pellisé M; Castellví-Bel S; Bessa X; Andreu M; Xicola RM; Llor X; Ruiz-Ponte C; Carracedo A; Jover R; Castells A; Balaguer F;
PLoS One; 2014; 9(3):e91033. PubMed ID: 24643221
[TBL] [Abstract][Full Text] [Related]
32. CHFR promoter methylation indicates poor prognosis in stage II microsatellite stable colorectal cancer.
Cleven AH; Derks S; Draht MX; Smits KM; Melotte V; Van Neste L; Tournier B; Jooste V; Chapusot C; Weijenberg MP; Herman JG; de Bruïne AP; van Engeland M
Clin Cancer Res; 2014 Jun; 20(12):3261-71. PubMed ID: 24928946
[TBL] [Abstract][Full Text] [Related]
33. Promoter methylation of specific genes is associated with the phenotype and progression of colorectal adenocarcinomas.
Kim JC; Choi JS; Roh SA; Cho DH; Kim TW; Kim YS
Ann Surg Oncol; 2010 Jul; 17(7):1767-76. PubMed ID: 20077021
[TBL] [Abstract][Full Text] [Related]
34. Epigenomic analysis of aberrantly methylated genes in colorectal cancer identifies genes commonly affected by epigenetic alterations.
Kim YH; Lee HC; Kim SY; Yeom YI; Ryu KJ; Min BH; Kim DH; Son HJ; Rhee PL; Kim JJ; Rhee JC; Kim HC; Chun HK; Grady WM; Kim YS
Ann Surg Oncol; 2011 Aug; 18(8):2338-47. PubMed ID: 21298349
[TBL] [Abstract][Full Text] [Related]
35. Molecular correlates with MGMT promoter methylation and silencing support CpG island methylator phenotype-low (CIMP-low) in colorectal cancer.
Ogino S; Kawasaki T; Kirkner GJ; Suemoto Y; Meyerhardt JA; Fuchs CS
Gut; 2007 Nov; 56(11):1564-71. PubMed ID: 17339237
[TBL] [Abstract][Full Text] [Related]
36. CpG island methylator phenotype associates with low-degree chromosomal abnormalities in colorectal cancer.
Cheng YW; Pincas H; Bacolod MD; Schemmann G; Giardina SF; Huang J; Barral S; Idrees K; Khan SA; Zeng Z; Rosenberg S; Notterman DA; Ott J; Paty P; Barany F
Clin Cancer Res; 2008 Oct; 14(19):6005-13. PubMed ID: 18829479
[TBL] [Abstract][Full Text] [Related]
37. Genome-wide methylation profiling identified novel differentially hypermethylated biomarker MPPED2 in colorectal cancer.
Gu S; Lin S; Ye D; Qian S; Jiang D; Zhang X; Li Q; Yang J; Ying X; Li Z; Tang M; Wang J; Jin M; Chen K
Clin Epigenetics; 2019 Mar; 11(1):41. PubMed ID: 30846004
[TBL] [Abstract][Full Text] [Related]
38. No association of CpG island methylator phenotype and colorectal cancer survival: population-based study.
Jia M; Jansen L; Walter V; Tagscherer K; Roth W; Herpel E; Kloor M; Bläker H; Chang-Claude J; Brenner H; Hoffmeister M
Br J Cancer; 2016 Nov; 115(11):1359-1366. PubMed ID: 27811854
[TBL] [Abstract][Full Text] [Related]
39. 18q loss of heterozygosity in microsatellite stable colorectal cancer is correlated with CpG island methylator phenotype-negative (CIMP-0) and inversely with CIMP-low and CIMP-high.
Ogino S; Kawasaki T; Kirkner GJ; Ohnishi M; Fuchs CS
BMC Cancer; 2007 May; 7():72. PubMed ID: 17474983
[TBL] [Abstract][Full Text] [Related]
40. Identification of a CpG island methylator phenotype in adrenocortical carcinomas.
Barreau O; Assié G; Wilmot-Roussel H; Ragazzon B; Baudry C; Perlemoine K; René-Corail F; Bertagna X; Dousset B; Hamzaoui N; Tissier F; de Reynies A; Bertherat J
J Clin Endocrinol Metab; 2013 Jan; 98(1):E174-84. PubMed ID: 23093492
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
